NCT03493061View on ClinicalTrials.gov

A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2022

Conditions
Colo-rectal CancerLiver Metastases
Interventions
DRUG

Irinotecan

Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15

DRUG

Oxaliplatin

Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.

DRUG

Floxuridine

0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT03493061 - A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM | Biotech Hunter | Biotech Hunter